Linlin Cheng
- Infectious Diseases top 10%
- COVID-19 Clinical Research Studies 6
- SARS-CoV-2 and COVID-19 Research 4
- Rheumatology top 10%
- Systemic Lupus Erythematosus Research 7
- Otitis Media and Relapsing Polychondritis 6
- Eosinophilic Disorders and Syndromes 5
- Neurology top 10%
- Dermatology top 10%
-
- Ocular Diseases and Behçet’s Syndrome 12
-
- Inflammatory Myopathies and Dermatomyositis 6
-
- Vasculitis and related conditions 5
- Journals
- Frontiers in Immunology (8 papers)Clinical Rheumatology (6 papers)Journal of Clinical Laboratory Analysis (3 papers)
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Linlin Cheng
40 papers receiving 613 citations
Peers
Comparison fields: 5 of 84
- Infectious Diseases 240
- Rheumatology 97
- Neurology 96
- Internal Medicine 23
- Dermatology 53
Countries citing papers authored by Linlin Cheng
This map shows the geographic impact of Linlin Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linlin Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linlin Cheng more than expected).
Fields of papers citing papers by Linlin Cheng
This network shows the impact of papers produced by Linlin Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linlin Cheng. The network helps show where Linlin Cheng may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Linlin Cheng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 3 | |
| 4 | 2025 | 1 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 5 | |
| 8 | 2023 | 5 | |
| 9 | 2023 | 5 | |
| 10 | 2023 | 2 | |
| 11 | 2023 | 4 | |
| 12 | 2023 | 7 | |
| 13 | 2022 | 8 | |
| 14 | 2022 | 9 | |
| 15 | 2021 | 26 | |
| 16 | 2021 | 12 | |
| 17 | 2020 | 10 | |
| 18 | 2020 | 6 | |
| 19 | 2020 | 13 | |
| 20 | 2019 | 7 |
About Linlin Cheng
Linlin Cheng is a scholar working on Rheumatology, Ophthalmology, Genetics, Hematology and Dermatology, having authored 46 papers that have together received 628 indexed citations. Recurring topics across this work include Ocular Diseases and Behçet’s Syndrome (12 papers), Systemic Lupus Erythematosus Research (7 papers), COVID-19 Clinical Research Studies (6 papers), Inflammatory Myopathies and Dermatomyositis (6 papers), Otitis Media and Relapsing Polychondritis (6 papers), Eosinophilic Disorders and Syndromes (5 papers), Vasculitis and related conditions (5 papers) and SARS-CoV-2 and COVID-19 Research (4 papers). The work is most often cited by research in Infectious Diseases (240 citations), Rheumatology (97 citations), Neurology (96 citations), Internal Medicine (23 citations) and Dermatology (53 citations). Linlin Cheng has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Yongzhe Li, Haolong Li, Songxin Yan, Chenxi Liu, Haizhen Chen, Liubing Li, Haoting Zhan, Yongmei Liu, Yanfang Zhang and Xiaomeng Li. Their work appears in journals such as Frontiers in Immunology, Clinical Rheumatology, Journal of Clinical Laboratory Analysis, Virology Journal and Clinical & Experimental Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.